Scopolamine Market

Scopolamine Market Size

Scopolamine Market size was valued at around USD 419 million in 2023 and is estimated to grow at 5.3% CAGR from 2024 to 2032. Scopolamine, also known as hyoscine, is a tropane alkaloid derived from plants of the nightshade family (Solanaceae), such as henbane (Hyoscyamus Niger). It is primarily known for its anticholinergic properties, meaning it inhibits the action of the neurotransmitter acetylcholine in the central and peripheral nervous systems.

The rise in chronic diseases such as cardiovascular diseases, diabetes, and cancer has led to an increase in surgical interventions, many of which require effective management of preoperative and postoperative nausea and vomiting. According to the American Cancer Society, around 20 million new cancer cases were diagnosed globally in 2022, with 9.7 million deaths resulting from the disease. Projections indicate that by 2050, the number of cancer cases is expected to rise to 35 million, driven solely by anticipated population growth.

This surge in chronic diseases is stimulated by aging population, sedentary lifestyles, and unhealthy diets, resulting in a higher number of patients needing surgical procedures. Scopolamine is widely used to prevent and treat postoperative nausea and vomiting (PONV), a common complication following surgery. Thus, as hospitals and surgical centers focus on improving patient outcomes and comfort, the demand for scopolamine to alleviate nausea and vomiting will significantly increase.

Furthermore, increased global travel and a health-conscious population have driven greater recognition and diagnosis of motion sickness and related nausea. With more individuals experiencing motion sickness due to travel, scopolamine has emerged as an effective treatment. Improved awareness and diagnostics have further identified those can benefit from scopolamine, expanding its use beyond motion sickness to other nausea-related conditions such as chemotherapy-induced nausea, widening its market reach.

Scopolamine Market Trends

• Advancements in novel drug delivery systems have significantly improved the accessibility and administration of scopolamine, enhancing its efficacy and patient compliance. The development of scopolamine transdermal drug delivery systems, which is estimated to reach USD 61 billion by 2032, enables continuous drug delivery over typically three days, offering a more convenient option for patients compared to oral or injectable forms.
  
• Additionally, pharmaceutical advancements have facilitated the creation of sustained-release formulations, ensuring steady drug levels in the body and prolonged therapeutic effects.
  
• Therefore, these innovations collectively contribute to the improved delivery and performance of scopolamine, making it a more reliable option for patients in need of antiemetic treatment.
  

Scopolamine Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

Based on dosage form, the market is divided into transdermal patches, tablets, injectables, and other dosage forms. The transdermal patches segment of the market is forecasted to reach USD 293.8 million by 2032.

• Transdermal patches provide a convenient and non-invasive method for administering medication, including scopolamine, ensuring continuous and controlled delivery over an extended period. Patients favor this approach for its ease of use and reduced dosing frequency compared to oral or injectable alternatives.
  
• Further, advancements in patch technology, such as improved adhesion, enhanced drug permeation, and extended wear times, drive market growth by enhancing the efficacy and patient acceptance of scopolamine patches.

Learn more about the key segments shaping this market

Download Free PDF

Based on application, the scopolamine market is bifurcated into motion sickness, postoperative nausea and vomiting (PONV), and other applications. The motion sickness segment accounted for USD 203.9 million in 2023.

• Motion sickness is a prevalent issue for travelers across different modes of transportation, including cars, airplanes, boats, and trains. With global travel and tourism expand, so does the occurrence of motion sickness, fueling the need for effective remedies such as scopolamine.
  
• With its established efficacy, scopolamine is widely acknowledged as an effective treatment, alleviating symptoms such as nausea, dizziness, and vomiting by acting on the central nervous system. Its proven effectiveness makes it the preferred choice for individuals susceptible to motion sickness.
  

Based on route of administration, the scopolamine market is bifurcated into topical, oral, and parenteral. The oral segment accounted for USD 105.1 million in 2023.

• Oral administration of scopolamine has been a longstanding method for delivering the medication. It involves the ingestion of tablets or liquid formulations, making it a familiar and accessible option for both healthcare providers and patients.
  
• Oral formulations offer versatility in dosing, allowing for precise adjustment according to individual patient needs. This flexibility makes oral scopolamine suitable for a wide range of indications, including motion sickness, postoperative nausea and vomiting, and other conditions causing nausea and vomiting.
  

Based on distribution channel, the scopolamine market is bifurcated into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment accounted for USD 204.1 million in 2023.

• High patient volume in hospitals, coupled with the need for expert medical prescription and administration, ensures the appropriate use of scopolamine for conditions like motion sickness and postoperative nausea.
  
• Hospitals offer integrated care, leading to increased demand for medications dispensed through their pharmacies. Additionally, the higher trust and compliance associated with hospital pharmacies, their access to specialized formulations, and bulk institutional purchases contribute to the significant revenue in this segment.

Looking for region specific data?

Download Free PDF

• The growth of the scopolamine market in the U.S., projected to reach USD 241.3 million by 2032.
  
• The aging population in the U.S. contributes to a higher prevalence of chronic diseases and associated symptoms such as nausea and vomiting, creating a greater demand for effective treatments such as scopolamine.
  
• Additionally, the expanding applications of scopolamine beyond motion sickness, including postoperative nausea and vomiting (PONV) and chemotherapy-induced nausea, align with the increasing emphasis on comprehensive symptom management in U.S. healthcare settings.
  

The scopolamine market in UK is expected to experience significant and promising growth from 2024 to 2032.

• Advancements in drug delivery systems, particularly transdermal patches, enhance the convenience and effectiveness of administering scopolamine, resonating well with the preferences of both healthcare professionals and patients in the UK.
  
• These innovations improve patient compliance and satisfaction, thereby contributing to the market growth.
  

Japan scopolamine market is anticipated to witness lucrative growth between 2024 – 2032.

• Japan has a robust pharmaceutical industry characterized by ongoing research and development activities. Pharmaceutical companies are continually exploring new formulations, indications, and therapeutic applications for existing medications such as scopolamine.
  
• This innovation-driven environment fosters the expansion of the market as new products and formulations enter the market, catering to diverse patient needs.
  

The scopolamine market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.

• Saudi Arabia has been increasingly investing in its healthcare infrastructure and services. The country aims to enhance healthcare accessibility and quality, leading to a corresponding increase in healthcare expenditure.
  
• This growth in investment translates into greater access to medications, including scopolamine, for the population.
  

Scopolamine Market Share

The scopolamine sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command considerable influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Scopolamine Market Companies

Some of the eminent market participants operating in the scopolamine industry include:

• Alchem International Pvt. Ltd.
• Australian Alkaloids Ltd.
• Baxter International Inc.
• Caleb Pharmaceuticals, Inc.
• Fine Chemicals Corporation
• Fresenius SE & Co. KGaA
• GSK plc
• Ingenus Pharmaceuticals
• Mylan N.V.
• Myungmoon Pharm. Co., Ltd.
• Novartis AG
• Perrigo Company plc
• Pfizer Inc.
• Phytex Australia
• Teva Pharmaceutical Industries Limited
  

Scopolamine Industry News:

• In August 2022, Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA, completed the acquisition of a majority stake in mAbxience Holding S.L., significantly bolstering its presence in the high-growth pharmaceutical, biopharmaceutical, and medtech markets. This acquisition provided the company with a competitive edge in the market.
  
• In October 2019, Perrigo Company plc announced the relaunch of their AB-rated generic equivalent of Transderm Scop (scopolamine 1.5 mg). This product launch provided the company with a competitive edge in the market.
  

The scopolamine market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Dosage Form

• Transdermal patches
• Tablets
• Injectables
• Other dosage forms

Market, By Application

• Motion sickness
• Postoperative nausea and vomiting (PONV)
• Other applications

Market, By Route of Administration

• Topical
• Oral
• Parenteral

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe 
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America 
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa